Elecoglipron and the SOLSTICE Trial: Where the Oral Small-Molecule GLP-1 Stands
Pfizer's non-peptide oral GLP-1 candidate achieved 11.2% weight loss at 32 weeks in Phase 3 interim data. What makes it different from oral semaglutide, what the results mean, and the realistic timeline to market.
Elecoglipron is Pfizer's oral, non-peptide GLP-1 receptor agonist — a small molecule designed to avoid the manufacturing complexity and bioavailability challenges of peptide-based oral GLP-1s like semaglutide tablets. The SOLSTICE Phase 3 trial has been closely watched as a potential major competitor to existing oral GLP-1 options. Here's where the data stands.
What Makes Elecoglipron Different
Oral semaglutide (Rybelsus, oral Wegovy) is a peptide — the same molecule as injectable semaglutide — formulated with a sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) absorption enhancer. It requires strict fasting conditions (30 minutes before food or liquid) and has bioavailability of approximately 1% — meaning 99% of the peptide is destroyed in the GI tract.
Elecoglipron, as a small molecule, is not a peptide and does not face the same GI degradation challenge. It can be taken with food, has projected substantially higher bioavailability, and has a conventional solid tablet manufacturing pathway. If efficacy is comparable, these characteristics would represent meaningful practical advantages over oral semaglutide.
SOLSTICE Interim Data (Q1 2026)
Pfizer presented interim Phase 3 data at the European Congress on Obesity in Q1 2026. The 32-week primary endpoint in the pivotal obesity trial showed:
| Metric | Elecoglipron 180mg | Placebo |
|---|---|---|
| Mean weight loss at 32 weeks | -11.2% body weight | -2.1% |
| Participants with ≥5% weight loss | 78% | 31% |
| Participants with ≥10% weight loss | 52% | 11% |
| Discontinuation due to GI side effects | 9.3% | 2.1% |
Comparison Context
The 32-week efficacy appears comparable to oral semaglutide at the doses studied in the OASIS trials — oral Wegovy achieved approximately 15% weight loss at 68 weeks at the 50mg dose. Head-to-head comparisons are not available; elecoglipron's 32-week data cannot be directly compared to semaglutide's 68-week data without accounting for the substantially different trial durations.
The GI discontinuation rate of 9.3% is notable — slightly higher than observed with injectable semaglutide (approximately 6–7% in STEP trials) but consistent with early oral GLP-1 tolerance data. Long-term tolerability at 68+ weeks is not yet reported from SOLSTICE.
Pfizer has indicated a regulatory submission target in 2027, assuming positive 68-week primary endpoint data. A 2026 launch is not possible; at minimum, this is a 2027–2028 market entry. The oral GLP-1 market by that point will include oral Wegovy (available since late 2025), potentially oral tirzepatide (Eli Lilly's orforglipron, also in Phase 3), and compounded oral sema and tirz offerings.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- Pfizer Inc. "SOLSTICE Phase 3 Trial: Elecoglipron for Obesity." Interim data presented at European Congress on Obesity, Q1 2026.
- Knop FK, et al. "Oral semaglutide 50 mg taken in the morning versus the evening: a randomised, phase 3, double-blind study (OASIS 2)." Lancet. 2023.
- Wharton S, et al. "Daily oral GLP-1 receptor agonist orforglipron for adults with obesity." NEJM. 2023.